Compare INHD & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INHD | AKTX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.1M |
| IPO Year | 2023 | 2014 |
| Metric | INHD | AKTX |
|---|---|---|
| Price | $1.12 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | ★ 268.0K | 198.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,846,250.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 221.43 | N/A |
| 52 Week Low | $0.06 | $0.22 |
| 52 Week High | $15.90 | $1.72 |
| Indicator | INHD | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 51.89 |
| Support Level | $1.04 | $0.25 |
| Resistance Level | $1.17 | $0.27 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 49.92 | 72.22 |
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.